# Embecta share price today (Embecta Corp., EMBC)

> Embecta Corp.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. EMBC · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/embc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from fewer quarters than usual
- Price: $6.08 (−54.4% in a year)
- P/E: 4.1× (higher than 62% of the last 10 months)
- Revenue (Jun 2026): $272 M (−8.1% on a year ago)
- Profit (Jun 2026): $21.1 M (−53.6% on a year ago)
- Operating margin: 23.7% (−12.1 points on a year ago)
- ROE: −15%, FY25
- ROIC: 20.4%, against a 5.5% cost of capital: +14.9 points

The main question: yearly earnings per share moved +20.9% while the share price moved −54.4%. ## What is the Embecta share price today? Embecta Corp.'s share price was $6.08 at the close on 3 November 2026. That is 4.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $15, and at that close it sat 26% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved −42% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Embecta pay? Embecta Corp. paid $0.46 per share over the last four reported quarters. The most recent declaration was $0.01 for Jun 2026. At today's price of $6.08 that is a yield of 7.57%, based on dividends already paid, not a forecast. ## Which stock lists is Embecta on? Embecta is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Embecta profitable? Embecta Corp. earned $21.1 M of net profit in the Jun 2026 quarter, −53.6% on the same quarter a year earlier. Full-year FY25 profit was $95.4 M. Over 4 years profit has grown −30.7% a year on average. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned $45.5 M. 1 of the last 11 reported quarters were loss-making. For the full year, FY25 profit was $95.4 M (+21.8% on the year before). Why profit moved: revenue changed −8.1% on a year earlier and the margin moved −12.1 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −30.1% and revenue −7.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Embecta make, and is it growing? Embecta Corp. reported $272 M of revenue in the Jun 2026 quarter, −8.1% on the same quarter a year earlier. Over 4 years it has grown −1.9% a year on average. The last full year, FY25, came in at $1.1 B. The last four reported quarters add to $1.0 B. FY25 revenue was $1.1 B, −3.8% on the year before. Recent pace: the last four quarters grew −7.6% on average, against −1.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −7.6%, against −4.6% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Embecta keep? Embecta Corp.'s operating margin was 23.7% in the Jun 2026 quarter, 12.1 percentage points lower than the same quarter a year ago. Across 5 years it has been between 25.4% and 42.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −12.1 percentage points on the year while gross margin changed −10.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Embecta's profit turning into cash? Over the last 3 years, 121% of Embecta Corp.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $192 M of operating cash against $95.4 M of profit. After $9.3 M of spending on assets, $182 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Embecta's cash go? Embecta Corp. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $51.6 M on assets over the last 3 years. Averaged over those years that is 1.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $51.6 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Embecta's P/E ratio, and how does it compare with its own history? Embecta Corp.'s P/E is 4.1×, in the middle of its own history: higher than 62% of past readings. Its usual P/E (the middle reading) is 3.8×, over 10 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +20.9% while the price moved −54.4%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Embecta business getting better or worse? Embecta Corp.'s business is getting worse. Revenue and profit growth are shrinking: revenue growth is −7.6% in the latest quarter, against +1.3% at its best in 12 quarters. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Embecta earn on its capital? Embecta Corp. earned a ROE of −15% in FY25. That is up from a low of −25% in FY22. Its return on capital used (ROIC) is 14.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.8% net margin and 0.99× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.8% net margin × 0.99× asset turnover × −1.68× leverage (assets divided by equity) ≈ −14.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 20.4% − 5.5% = +14.9 percentage points. The 5.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 20.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 25.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Embecta have too much debt? Embecta Corp.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.01 in FY21 to −2.22 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Embecta shareholding pattern? 10.7% of Embecta Corp.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Embecta from balance-sheet trouble? For Embecta Corp., the Z-score is 1.44. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.44 is inside the danger zone, so the balance sheet is a real risk. ## How does Embecta rank in its industry? There is no score against its industry: Embecta Corp. is not among the largest members shown in this industry comparison for Medical Instruments & Supplies. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Embecta compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Embecta in size? Embecta is the 33rd largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: STAAR Surgical Company, Anteris Technologies Global Corp. and AngioDynamics, Inc. Just below it: Sanara MedTech Inc., OraSure Technologies, Inc. and Utah Medical Products, Inc. ### Medical Instruments & Supplies companies close in size

1. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) $1.3 billion
2. [Anteris Technologies Global Corp.](https://www.sectoralpha.in/us/stocks/avr) $546 million
3. [AngioDynamics, Inc.](https://www.sectoralpha.in/us/stocks/ango) $493 million
4. Embecta Corp. $344 million
5. [Sanara MedTech Inc.](https://www.sectoralpha.in/us/stocks/smti) $296 million
6. [OraSure Technologies, Inc.](https://www.sectoralpha.in/us/stocks/osur) $243 million
7. [Utah Medical Products, Inc.](https://www.sectoralpha.in/us/stocks/utmd) $222 million

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Orchestra BioMed Holdings, Inc.](https://www.sectoralpha.in/us/stocks/obio) $355 million · Biotechnology
2. [Farmland Partners Inc.](https://www.sectoralpha.in/us/stocks/fpi) $354 million · REIT - Specialty
3. Embecta Corp. $354 million
4. [Community Healthcare Trust Incorporated](https://www.sectoralpha.in/us/stocks/chct) $353 million · REIT - Healthcare Facilities
5. [Eagle Point Credit Company](https://www.sectoralpha.in/us/stocks/ecc) $352 million · Asset Management

## What else do people ask about Embecta? ### What were Embecta's latest quarterly results? Embecta Corp. reported revenue of $272 M and net profit of $21.1 M for the Jun 2026 quarter. Revenue fell 8.1% and profit fell 53.6% compared with a year earlier. Earnings per share were $0.36. The operating margin was 23.7%, 12.1 percentage points lower than a year earlier (as of 3 November 2026). ### What is Embecta's market cap? Embecta Corp.'s market capitalisation is $344 M at a stock price of $6.08. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Embecta performing? Embecta Corp.'s latest readings are below. In its latest quarter, revenue fell 8.1% and profit fell 53.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Embecta's stock price go up? This page does not forecast Embecta Corp.'s stock price. What it shows instead: the stock price is $6.08. Its P/E of 4.1× is higher than 62% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Embecta in its business cycle? Embecta Corp.'s FY25 operating margin was 29.2%, against a 5-year range of 25.4% to 42.2%: the low end of its own range, which is often where recoveries start. The latest quarter was 23.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Embecta story? The main question: yearly earnings per share moved +20.9% while the share price moved −54.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Embecta a stock worth studying right now? What the numbers show: Embecta Corp.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.